Seminars in Nephrology
Volume 29, Issue 6 , Pages 610-620 , November 2009

Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly

  • Devasmita Choudhury, MD

      Affiliations

    • The University of Texas Southwestern Medical Center, In-Center and Home Dialysis, Dallas VA Medical Center, Dallas, TX
    • ,
  • Meryem Tuncel, MD

      Affiliations

    • Department of Nephrology and Hypertension, Texas Tech University Health Sciences Center, Lubbock, TX
    • ,
  • Moshe Levi, MD

      Affiliations

    • Department of Medicine, The University of Colorado Denver, Staff Physician, Denver VA Medical Center, Denver, CO
    • Corresponding Author InformationAddress reprint requests to Moshe Levi, MD, 12700 East 19th Avenue, Research 2, Room 7002, Aurora, CO 80045

References 

  1. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–495
  2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  3. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49:1428–1434
  4. United States Renal Data System. Annual Data Report. Bethesda, MD: US Department of Public Health and Human Services, Public Health Service, National Institutes of Health; 2006;
  5. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166:1884–1891
  6. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl. 2005;99:S87–S93
  7. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908–1919
  8. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12:1908–1915
  9. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260–269
  10. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–178
  11. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  12. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol. 2008;28:958–973
  13. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384
  14. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:F262–F272
  15. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73–77
  16. Mordasini R, Frey F, Flury W, Klose G, Greten H. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med. 1977;297:1362–1366
  17. Koniger M, Quaschning T, Wanner C, Schollmeyer P, Kramer-Guth A. Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int Suppl. 1999;71:S248–S250
  18. Gonzalez AI, Schreier L, Elbert A, et al. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients. Metabolism. 2003;52:116–121
  19. Dursun B, Dursun E, Capraz I, Ozben T, Apaydin A, Suleymanlar G. Are uremia, diabetes, and atherosclerosis linked with impaired antioxidant mechanisms?. J Investig Med. 2008;56:545–552
  20. Ramos R, Martinez-Castelao A. Lipoperoxidation and hemodialysis. Metabolism. 2008;57:1369–1374
  21. Annuk M, Fellstrom B, Akerblom O, Zilmer K, Vihalemm T, Zilmer M. Oxidative stress markers in pre-uremic patients. Clin Nephrol. 2001;56:308–314
  22. Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol. 1999;51:233–241
  23. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem. 2008;41:381–386
  24. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis?. Kidney Int. 1994;45:876–883
  25. Korczynska J, Stelmanska E, Nogalska A, et al. Upregulation of lipogenic enzymes genes expression in white adipose tissue of rats with chronic renal failure is associated with higher level of sterol regulatory element binding protein-1. Metabolism. 2004;53:1060–1065
  26. Chmielewski M, Sucajtys-Szulc E, Kossowska E, Swierczynski J, Rutkowski B, Boguslawski W. Increased gene expression of liver SREBP-2 in experimental chronic renal failure. Atherosclerosis. 2007;191:326–332
  27. Chmielewski M, Sucajtys E, Swierczynski J, Rutkowski B, Boguslawski W. Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure. Mol Cell Biochem. 2003;246:187–191
  28. Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism. 2007;56:1714–1718
  29. Kim HJ, Vaziri ND. Sterol regulatory element-binding proteins, liver X receptor, ABCA1 transporter, CD36, scavenger receptors A1 and B1 in nephrotic kidney. Am J Nephrol. 2009;29:607–614
  30. Zhou Y, Zhang X, Chen L, et al. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol. 2008;295:F662–F671
  31. Kim CH, Kim HJ, Mitsuhashi M, Vaziri ND. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome. Metabolism. 2007;56:1377–1382
  32. Jiang T, Liebman SE, Lucia MS, Li J, Levi M. Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int. 2005;68:2608–2620
  33. Nogalska A, Sucajtys-Szulc E, Swierczynski J. Leptin decreases lipogenic enzyme gene expression through modification of SREBP-1c gene expression in white adipose tissue of aging rats. Metabolism. 2005;54:1041–1047
  34. Pallottini V, Martini C, Cavallini G, et al. Modified HMG-CoA reductase and LDLr regulation is deeply involved in age-related hypercholesterolemia. J Cell Biochem. 2006;98:1044–1053
  35. Vila L, Roglans N, Alegret M, et al. Hypertriglyceridemia and hepatic steatosis in senescence-accelerated mouse associate to changes in lipid-related gene expression. J Gerontol A Biol Sci Med Sci. 2007;62:1219–1227
  36. Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes. 2007;56:2485–2493
  37. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–191
  38. Piper MD, Bartke A. Diet and aging. Cell Metab. 2008;8:99–104
  39. Martini C, Pallottini V, Cavallini G, Donati A, Bergamini E, Trentalance A. Caloric restrictions affect some factors involved in age-related hypercholesterolemia. J Cell Biochem. 2007;101:235–243
  40. Zhu M, Miura J, Lu LX, et al. Circulating adiponectin levels increase in rats on caloric restriction: the potential for insulin sensitization. Exp Gerontol. 2004;39:1049–1059
  41. Zhu M, de Cabo R, Lane MA, Ingram DK. Caloric restriction modulates early events in insulin signaling in liver and skeletal muscle of rat. Ann N Y Acad Sci. 2004;1019:448–452
  42. Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008;8:347–358
  43. Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008;8:333–341
  44. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer?. Nat Rev Cancer. 2009;9:123–128
  45. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins—novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008;7:841–853
  46. Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007;6:759–767
  47. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  48. Zhang QL, Koenig W, Raum E, Stegmaier C, Brenner H, Rothenbacher D. Epidemiology of chronic kidney disease: results from a population of older adults in Germany. Prev Med. 2009;48:122–127
  49. Roderick PJ, Atkins RJ, Smeeth L, et al. Detecting chronic kidney disease in older people; what are the implications?. Age Ageing. 2008;37:179–186
  50. Pizzarelli F, Lauretani F, Bandinelli S, et al. Predictivity of survival according to different equations for estimating renal function in community-dwelling elderly subjects. Nephrol Dial Transplant. 2009;24:1197–1205
  51. Culleton BF, Hemmelgarn BR. Is chronic kidney disease a cardiovascular disease risk factor?. Semin Dial. 2003;16:95–100
  52. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  53. Go AS, Lo JC. Epidemiology of non-dialysis-requiring chronic kidney disease and cardiovascular disease. Curr Opin Nephrol Hypertens. 2006;15:296–302
  54. Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008;168:2212–2218
  55. Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol. 2008;102:1668–1673
  56. Abrams J, Vela BS, Coultas DB, Samaan SA, Malhotra D, Roche RJ. Coronary risk factors and their modification: lipids, smoking, hypertension, estrogen, and the elderly. Curr Probl Cardiol. 1995;20:533–610
  57. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  58. Windler E, Schoffauer M, Zyriax BC. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diab Vasc Dis Res. 2007;4:136–142
  59. Wenger NK. Dyslipidemia as a risk factor at elderly age. Am J Geriatr Cardiol. 2004;13:4–9
  60. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015–3023
  61. Kuller LH, Shemanski L, Psaty BM, et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995;92:720–726
  62. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis (A model analogous to atherosclerosis). Am J Nephrol. 1988;8:261–271
  63. Joles JA, Kunter U, Janssen U, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000;11:669–683
  64. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301
  65. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–2091
  66. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–850
  67. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  68. Levi M. Do statins have a beneficial effect on the kidney?. Nat Clin Pract Nephrol. 2006;2:666–667
  69. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809–2816
  70. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102:52–60
  71. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134:931–940
  72. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  73. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range (Results of the Cholesterol and Recurrent Events (CARE) trial). Ann Intern Med. 1998;129:681–689
  74. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211–4218
  75. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115:700–707
  76. Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: collaborative atovastatin diabetes study (CARDS). Diabetes Care. 2006;29:2378–2384
  77. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007;147:1–9
  78. Maroo BP, Lavie CJ, Milani RV. Efficacy and Safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17:92–100
  79. Maroo BP, Lavie CJ, Milani RV. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction—are all HMG-CoA reductase inhibitors alike?. Drugs Aging. 2008;25:649–664
  80. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med. 2001;111:390–400
  81. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  82. Jardine AG, Holdaas H, Fellstrom B, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study. Am J Transplant. 2004;4:988–995
  83. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98–104
  84. Pierides AM, Alvarez-Ude F, Kerr DN. Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet. 1975;2:1279–1282
  85. Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients treated by chronic hemodialysis (Report of the Diaphane collaborative study). Nephron. 1982;31:103–110
  86. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  87. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887–1893
  88. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303
  89. Fellstrom BC, Jardine AD, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–1407
  90. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;84:S207–S210

PII: S0270-9295(09)00149-1

doi: 10.1016/j.semnephrol.2009.07.006

Seminars in Nephrology
Volume 29, Issue 6 , Pages 610-620 , November 2009

Article Tools

* Image Usage & Resolution